Gilead says Remdesivir Drug helped moderately ill Covid-19 patients


PTI, Jun 2, 2020, 12:26 PM IST

Washington: A California biotech company said on Monday that its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalised patients with Covid-19.

Gilead Sciences gave few details on Monday, but said full results would soon be published in a medical journal.

Remdesivir is the only treatment that’s been shown in a rigorous experiment to help fight the coronavirus. A large study led by the National Institutes of Health recently found it could shorten average recovery time from 15 days to 11 days in hospitalised patients with severe disease.

The drug is given through an IV and is designed to interfere with an enzyme the virus uses to copy its genetic material. It’s approved for treating Covid-19 in Japan and is authorised for emergency use in the US for certain patients.

The company-led study involved nearly 600 patients who had moderate pneumonia but did not need oxygen support. All were randomly assigned to get five or 10 days of the drug plus standard care, or standard care alone. Patients and their doctors knew who was getting what, which limits the objectivity of the results.

By the 11th day in the study, those on five days of remdesivir were 65% more likely to improve by at least one on a seven-point scale, Gilead said.

Ten days of treatment did not prove better than standard care alone.

There were no deaths among patients on five days of the drug, two among those on 10 days, and four among patients getting standard care alone. Nausea and headache were a little more common among those on the drug.
The study has some limitations, but “there was a control group which does help verify that remdesivir has some benefits,” said Dr Radha Rajasingham, an infectious disease specialist at the University of Minnesota Medical Center in Minneapolis who had no role in the work.

Since there are limited supplies of the experimental drug, finding benefit from five versus 10 days means more people can be treated, she added.

In a note to investors, Evercore ISI analyst Umer Raffat noted that the study’s main goal was changed partway through, from the percentage of patients discharged within two weeks to the scale of improvement after 11 days.

“A fair amount of critical data,” such as hospital discharge information, has not been disclosed, he wrote.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Kannada Sahitya Sammelana: Food distribution creates stir

Rohit gets hit in nets, practice pitches on slower side

India & Kuwait elevate ties to strategic level; ink defence pact after PM Modi meets top Kuwaiti leaders

In Kuwait, PM Modi meets yoga practitioner, other influencers from Gulf country

Notorious gangster wanted in UAPA case arrested at Nepal border

Mandhana, Renuka blow away West Indies in first ODI

‘Condition critical’, say doctors as farmer leader Dallewal’s fast enters 27th day

Related Articles More

‘Faster walkers’ had significantly lower risk of diabetes, hypertension: Study

World Meditation Day 2024: Celebrating inner peace and well-being

Virus causing gut infections could play role in development of Alzheimer’s: Study

Air pollution linked to more hospitalisations for all causes, mental illness too, study finds

Plant-based meat alternatives linked to increased risk of depression in vegetarians, study finds

MUST WATCH

Tulunadu Daivaradane

Feeding Birds with Creative Paddy Art!

Areca Nut

HOTEL SRI DURGA BHAVANA

Harish Poonja


Latest Additions

Kannada Sahitya Sammelana: Food distribution creates stir

Rohit gets hit in nets, practice pitches on slower side

India & Kuwait elevate ties to strategic level; ink defence pact after PM Modi meets top Kuwaiti leaders

In Kuwait, PM Modi meets yoga practitioner, other influencers from Gulf country

Notorious gangster wanted in UAPA case arrested at Nepal border

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.